Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Plenvu powder for oral solution

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Ascorbic acid, Macrogol 3350, Potassium chloride, Sodium ascorbate, Sodium chloride, Sodium sulfate, anhydrous may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Ascorbic acid, Macrogol 3350, Potassium chloride, Sodium ascorbate, Sodium chloride, Sodium sulfate, anhydrous

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Plenvu contains the combination of active substances macrogol 3350, sodium ascorbate, sodium sulfate anhydrous, ascorbic acid, sodium chloride and potassium chloride. Plenvu is a laxative. Plenvu is intended for adults 18 years of age and older prior to any clinical procedure requiring a clean bowel. Plenvu cleans your bowel by causing you to have diarrhoea.

What you need to know before you take it

e Plenvu Do not take Plenvu:  if you are allergic (hypersensitive) to the active substances or any of the other ingredients of Plenvu (listed in section 6)  if you have a blockage in your bowel (bowel obstruction)  if you have an opening in the wall of your stomach or bowel (bowel perforation)  if you have paralysis of the gut (ileus) 1

 if you experience problems with food and fluid emptying from your stomach (e.g. gastric paresis, gastric retention)  if you suffer from phenylketonuria. This is a hereditary inability of the body to use a particular amino acid. Plenvu contains a source of phenylalanine  if your body is unable to produce enough glucose-6-phosphate dehydrogenase  if you have a very dilated bowel (toxic megacolon) Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Plenvu if any of the below are applicable to you. If you:  have heart problems and/or heart rhythm problems  have kidney problems and/or dehydration  have heart failure, severe kidney problems or are taking blood pressure medicine  have stomach or bowel problems, including bowel inflammation  have problems with swallowing (see also Food and drink with Plenvu)  have a high or low blood salt level (e.g. sodium, potassium)  have any other medical conditions (e.g. seizures)  have epilepsy or a history of convulsions Plenvu should not be given to patients with impaired consciousness without medical supervision. If you are in poor health or have a serious medical condition, you should be particularly aware of the possible side effects listed in section 4. Contact your doctor, pharmacist or nurse if you are concerned. If you experience sudden abdominal pain or rectal bleeding when taking Plenvu for bowel preparation, contact your doctor or seek medical advice immediately. If you experience (blood) vomiting followed by sudden chest, neck or abdominal pain, difficulty swallowing or difficulty breathing when taking Plenvu, stop taking medicine and promptly contact your doctor. Children and adolescents Plenvu is not recommended for use in children under 18 years of age. Other medicines and Plenvu Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines (including oral contraceptives).

2

Medicines taken by mouth could be flushed through the gastrointestinal tract and may not be absorbed properly when taken one hour before, during and one hour after you have taken Plenvu. If taking oral contraceptives you may need to use additional forms of contraception (e.g. condom) to prevent pregnancy. Food and drink with Plenvu On the day before the clinical procedure you can eat a light breakfast followed by a light lunch: For the Two-day split dosing schedule, OR the Day before dosing schedule you must finish eating lunch at least 3 hours before you start taking Plenvu, after which you may only consume clear fluids. For the Morning only dosing schedule you may have clear soup and/or plain yogurt for dinner (which should be completed by approximately 20.00H). You may only consume clear fluids from after dinner on the evening before the clinical procedure. Note: For information regarding the dosing schedules refer to section 3. No breakfast is allowed on the morning of the clinical procedure. Continue to drink clear fluids before, during, and after you take Plenvu to help prevent fluid loss (dehydration). It is important for you to drink the additional prescribed amounts of clear fluids. Examples of clear fluids are water, clear soups, herbal tea, black tea or coffee (without milk), soft drinks/diluted cordials and clear fruit juices (without pulp). Important:  Do not drink alcohol, milk, anything coloured red or purple (e.g. blackcurrant juice) or any other drinks containing pulp material.  Do not eat while taking Plenvu and until after your clinical procedure. Consumption of all fluids should be stopped at least:  two hours before the clinical procedure when under general anaesthesia, or  one hour before the clinical procedure without general anaesthesia. If you need to thicken fluids in order to swallow them safely, Plenvu may counteract the effect of the thickener. Pregnancy, breast-feeding and fertility

3

There are no data on the use of Plenvu during pregnancy or breast-feeding and is therefore not recommended. It should only be used if considered essential by the doctor. If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking Plenvu. Driving and using machines Plenvu does not affect your ability to drive or use machines. Plenvu contains sodium, potassium and a source of phenylalanine This medicinal product contains 458.5 mmol (10.5 g) sodium per course of treatment. This is to be taken into consideration by patients on a controlled sodium diet. This medicinal product contains 29.4 mmol (1.1 g) potassium per course of treatment. This should be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet. Plenvu contains a source of phenylalanine which may be harmful for people with phenylketonuria. It also contains ascorbate which may be harmful for people with glucose-6-phosphate dehydrogenase deficiency.

How to take it

Plenvu Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure. Before you take Plenvu, please read carefully the following instructions. You need to know:  When to take Plenvu  How to prepare Plenvu  How to drink Plenvu  What you should expect to happen When to take Plenvu Your treatment with Plenvu must be completed before your clinical procedure. This course of treatment may be taken as divided doses as described below: Two-day split dosing schedule Dose 1 taken in the evening before the clinical procedure and Dose 2 in the morning of the day of the clinical procedure approximately 12 hours after the start of the first dose, or

4

Morning only dosing schedule Dose 1 and Dose 2 taken in the morning of the day of the clinical procedure; the second dose should be taken a minimum of 2 hours after the start of the first dose, or Day before dosing schedule Dose 1 and Dose 2 taken in the evening of the day before the clinical procedure; the second dose should be taken a minimum of 2 hours after the start of the first dose. Your doctor will inform you which dosing schedule to follow. DO NOT add any other ingredients to the doses. Do not eat while taking Plenvu and until after your clinical procedure. For information regarding the timing of meals before taking Plenvu refer to section 2. How to prepare Plenvu Dose 1 1. Open the carton and remove the Dose 1 sachet. 2. Pour the contents of Dose 1 into a measuring container that can hold 500 ml of fluid. 3. Add water to make up to 500 ml and stir until all the powder has dissolved. This may take up to approximately 8 minutes.

How to drink Plenvu Dose 1 Drink the 500 ml Dose 1 and 500 ml of clear fluid over a period of 60 minutes. Alternating between the reconstituted solution and clear fluid is acceptable. Try to drink a glassful every 10 to 15 minutes. Clear fluid may include water, clear soup, diluted cordials/clear fruit juice (without pulp), tea or coffee without milk.

5

How to prepare Plenvu Dose 2 1. When you are ready to take Dose 2 pour the contents of Dose 2 Sachet A and Dose 2 Sachet B into a measuring container that can hold 500 ml of fluid. 2. Add water to make up to 500 ml and stir until all the powder has dissolved. This may take up to approximately 8 minutes.

How to drink Plenvu Dose 2 When directed based on the recommended dosing schedule, make up and drink the 500 ml Dose 2 and 500 ml of clear fluid over a period of 60 minutes. Alternating between the reconstituted solution and clear fluid is acceptable.

Additional clear fluid may be drunk throughout the bowel preparation process, i.e. before, during, and after you take Plenvu, but you must stop drinking 1-2 hours prior to your clinical procedure. Drinking clear fluids will help prevent fluid loss (dehydration). What you should expect to happen When you start drinking the Plenvu solution, it is important that you stay close to a toilet. At some point, you will start to experience watery bowel movements. This is quite normal and indicates that the Plenvu solution is working. You may have stomach area bloating before you have your first bowel movement. If you follow these instructions, your bowel will be clear, and this will help you to have a successful examination. You should allow sufficient time after your bowel movements have subsided to travel to the clinic/hospital. If you take more laxatives than you should If you take Plenvu before or after taking other laxative products you may develop excessive diarrhoea, which can lead to dehydration. Take generous amounts of clear fluid. If you are worried contact your doctor or go to the nearest hospital accident and emergency department straight away. 6

If you forget to take Plenvu  If you forget to take Plenvu as instructed, take as soon as you realise you have not taken it and contact your doctor, pharmacist or nurse for advice prior to the clinical procedure.  It is important that you have allowed sufficient time to complete your course of Plenvu in order to ensure your bowel is fully cleaned at least 2 hours prior to the clinical procedure. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects Like all medicines Plenvu can cause side effects, although not everybody gets them. It is normal to get diarrhoea when you take Plenvu. If you do not have a bowel movement within 6 hours of taking Plenvu, stop the intake and contact your doctor immediately. If you have any of the following side effects stop taking Plenvu and tell your doctor immediately, as these may be symptoms of a severe allergic reaction:  Extreme fatigue  Palpitations  Rash or itching  Shortness of breath  Swelling of your face, ankles or other part of your body Stop taking Plenvu and immediately contact a doctor if you notice any of the following side effects:  Seizure Tell your doctor immediately if you have any of these symptoms while taking Plenvu as these may indicate a loss of too much body fluid (dehydration):  Dizziness  Headache  Urinating less often than normal  Vomiting Also, tell your doctor right away if you have severe stomach-area (abdomen) pain.

7

Rarely serious heart rhythm problems may occur (i.e. heart may feel like it's pounding, fluttering or beating irregularly, often for a few seconds or possibly a few minutes) with the use of laxatives for bowel preparation, especially in patients with underlying cardiac disease or salts disturbance. Talk to your doctor if the symptoms continue. Common side effects (may affect up to 1 in 10 people):  Dehydration  Nausea (feeling sick)  Vomiting Uncommon side effects (may affect up to 1 in 100 people)  Abdominal bloating and pain  Aches and pains  Allergic reaction  Chills  Fatigue  Headache or migraine  Hot flushes  Increased blood glucose level in diabetic patients  Increased heart rate  Palpitations  Soreness of the anus  Sleepiness  Temporary increase in blood pressure  Temporary increase in liver enzymes  Thirst  Various salt (electrolyte) imbalances  Weakness Not known side effects (frequency cannot be estimated from the available data)  Oesophageal rupture due to vomiting Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any

Possible side effects

not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

8

How to store it

Plenvu Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the sachets and carton, after "EXP". The expiry date refers to the last day of that month. Please note that the expiry dates may be different for each of the sachets and carton. Prior to opening do not store above 25°C. Keep prepared solutions below 25°C and drink it within 24 hours. The solutions may be stored in a refrigerator. The solutions must be covered. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Plenvu contains Dose 1 sachet contains the following active substances: Macrogol 3350 Sodium sulfate anhydrous Sodium chloride Potassium chloride

100 g 9g 2g 1g

The concentration of electrolyte ions when the first dose is made up to 500 ml of solution is as follows: Sodium Sulfate Chloride Potassium

160.9 mmol/500 ml 63.4 mmol/500 ml 47.6 mmol/500 ml 13.3 mmol/500 ml

9

Dose 1 also contains 0.79 g of sucralose (E955). Dose 2 (Sachets A and B) contains the following active substances: Sachet A: Macrogol 3350 Sodium chloride Potassium chloride

40 g 3.2 g 1.2 g

Sachet B: Sodium ascorbate Ascorbic acid

48.11 g 7.54 g

The concentration of electrolyte ions when the second dose (Sachets A and B) is made up to 500 ml of solution is as follows: Sodium Ascorbate Chloride Potassium

297.6 mmol/500 ml 285.7 mmol/500 ml 70.9 mmol/500 ml 16.1 mmol/500 ml

Excipients with known effect Dose 2 (Sachet A) also contains 0.88 g of aspartame (E951). The other ingredients are: mango flavour containing glycerol (E422), flavouring preparations, gum acacia (E414), maltodextrin (E1400) and natural flavouring substances; and fruit punch flavour containing flavouring preparations, gum acacia (E414), maltodextrin (E1400) and flavouring substances. For further information refer to section 2. What Plenvu looks like and contents of the pack This pack contains three sachets: Dose 1, Dose 2 Sachet A, and Dose 2 Sachet B. Plenvu powder for oral solution is available in packs containing 1 treatment and in packs containing 40, 80, 160 and 320 treatments. Not all pack sizes may be marketed. Marketing authorisation holder: Norgine Pharmaceuticals Limited ARC Uxbridge, Building 01, Sanderson Road, Uxbridge, UB8 1DH, UK

10

Manufacturers: Norgine Limited, New Road, Hengoed, Mid Glamorgan, CF82 8SJ, United Kingdom Or Norgine B.V. Antonio Vivaldistraat 150, 1083HP Amsterdam The Netherlands Or Norgine Pharma 29 rue Ethe Virton Dreux 28100 France

This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names: Belgium, Bulgaria, Czech Republic, Croatia, Denmark, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Luxembourg, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden, United Kingdom (Northern Ireland): PLENVU Austria, Netherlands, Spain: PLEINVUE This leaflet was last revised in May 2025

Other sources of information If you need the information on this leaflet in an alternative format, such as large print, or Braille please ring 0800 198 5000.

11

Frequently asked questions about Plenvu powder for oral solution

How do I take Plenvu powder for oral solution?

Plenvu powder for oral solution comes as oral solution. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Plenvu powder for oral solution?

The active substance in Plenvu powder for oral solution is ascorbic acid, macrogol 3350, potassium chloride, sodium ascorbate, sodium chloride, sodium sulfate, anhydrous.

Are there equivalent medicines to Plenvu powder for oral solution?

Medicines with the same active substance, strength and form include: MOVIPREP, powder for oral solution. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Plenvu powder for oral solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Plenvu powder for oral solution without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

  • Source: electronic medicines compendium (emc), Datapharm
  • Active substance: ascorbic acid, macrogol 3350, potassium chloride, sodium ascorbate, sodium chloride, sodium sulfate, anhydrous
  • Official document: view the original leaflet on emc →
Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Ascorbic acid (13 medicines), Ascorbic acid, macrogol 3350, potassium chloride, sodium ascorbate, sodium chloride, sodium sulfate, anhydrous (2 medicines), Potassium chloride (66 medicines), Sodium chloride (98 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Plenvu is indicated in adults for bowel cleansing prior to any procedure requiring a clean bowel.

4.2. Posology and method of administration

Posology

Adults and elderly

A course of treatment consists of two separate non-identical 500 ml doses of Plenvu. At least 500 ml of additional clear fluid, which may include water, clear soup, fruit juice without pulp, soft drinks, tea and/or coffee without milk must be taken with each dose.

This course of treatment can be taken according to a two-day or one-day dosing schedules as specified below:

Two-day dosing schedule:

• The first dose taken in the evening before the clinical procedure and the second dose in the morning of the day of the clinical procedure, approximately 12 hours after the start of the first dose.

One-day dosing schedules:

• Morning only dosing schedule with both doses taken in the morning of the day of the clinical procedure; the second dose should be taken a minimum of 2 hours after the start of the first dose, or

• Day before dosing schedule with both doses taken in the evening before the clinical procedure; the second dose should be taken a minimum of 2 hours after the start of the first dose.

The appropriate dosing schedule should be selected according to the timing of the clinical procedure.

Paediatric population

The safety and efficacy in children below 18 years of age has not yet been established. Plenvu is therefore not recommended for use in this population.

Patients with renal impairment

No special dosage adjustment is deemed necessary in patients with mild to moderate renal impairment. Patients with mild to moderate renal impairment were included in clinical studies.

Patients with hepatic impairment

No special dosage adjustment is deemed necessary in patients with mild to moderate hepatic impairment. Patients with elevated liver function tests were included in clinical studies.

Method of administration

For oral use.

Dose 1: The contents of the single sachet for dose 1 should be made up to 500 ml with water. The reconstituted solution, plus an additional 500 ml of clear fluid, should be taken over a period of 60 minutes. Alternating between the reconstituted solution and clear fluid is acceptable.

Dose 2: The contents of the two sachets (sachets A and B together) for dose 2 should be made up to 500 ml with water. The reconstituted solution, plus an additional 500 ml of clear fluid, should be taken over a period of 60 minutes. Alternating between the reconstituted solution and clear fluid is acceptable.

In some instances, the intake of the reconstituted solution may be slowed or temporarily discontinued (see section 4.4).

In addition to the fluids taken as part of the course of treatment, any amount of supplementary clear fluid (e.g. water, clear soup, fruit juice without pulp, soft drinks, tea and/or coffee without milk) may be taken throughout the bowel preparation process. Note: Avoid any fluid coloured red or purple (e.g. blackcurrant juice) as this can stain the bowel.

Consumption of all fluids should be stopped at least;

• two hours before the clinical procedure when under general anaesthesia, or

• one hour before the clinical procedure without general anaesthesia.

Information regarding meals

No solid food should be taken from the start of the course of treatment until after the clinical procedure.

Patients should be advised to allow adequate time after bowel movements have subsided to travel to the clinical unit.

Two-day split dosing schedule and day before dosing schedule:

The day before the clinical procedure, patients can have a light breakfast followed by a light lunch which must be completed at least 3 hours prior to the start of the first dose.

Morning only dosing schedule:

The day before the clinical procedure, patients can have a light breakfast followed by a light lunch, and clear soup and/or plain yogurt for dinner, which should be completed by approximately 20.00H.

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

4.3. Contraindications

Do not use in patients with known or suspected:

• hypersensitivity to the active substances or to any of the excipients listed in section 6.1

• gastrointestinal obstruction or perforation

• ileus

• disorders of gastric emptying (e.g. gastroparesis, gastric retention, etc.)

• phenylketonuria (due to presence of aspartame)

• glucose-6-phosphate dehydrogenase deficiency (due to presence of ascorbate)

• toxic megacolon

4.4. Special warnings and precautions for use

The fluid content of Plenvu when reconstituted with water does not replace regular fluid intake and adequate fluid intake must be maintained.

As with other macrogol containing products, allergic reactions including rash, urticaria, pruritus, angioedema and anaphylaxis are a possibility.

Caution should be used with the administration of Plenvu to frail or debilitated patients.

Plenvu should also be used with caution in patients with:

• impaired gag reflex, with the possibility of regurgitation or aspiration, or with diminished levels of consciousness. Such patients should be closely observed during administration especially if given via a nasogastric route

• severe renal impairment (creatinine clearance less than 30 ml/minute/1.73 m2)

• cardiac failure (grade III or IV of NYHA)

• those at risk of arrhythmia, for example those with or on treatment for cardiovascular disease, thyroid disease or electrolyte imbalance

• dehydration

• severe acute inflammatory bowel disease.

In debilitated fragile patients, patients with poor health, those with clinically significant renal impairment, arrhythmia and those at risk of electrolyte imbalance, the physician should consider performing a baseline and post-treatment electrolyte, renal function test and ECG as appropriate. Any suspected dehydration should be corrected for before use of Plenvu.

Cases of seizures associated with use of macrogol 3350 with electrolytes for bowel preparation were observed in patients either with or without prior history of seizures. These cases were mostly associated with electrolyte abnormalities such as severe hyponatraemia (see section 4.8). Use caution when prescribing macrogol 3350 with electrolytes in patients with a history of seizures, at increased risk of seizure or at risk of electrolyte disturbance. In case of neurologic symptoms, fluid and electrolyte abnormalities should be corrected.

There have been rare reports of serious arrhythmias including atrial fibrillation associated with the use of ionic osmotic laxatives for bowel preparation. These occur predominantly in patients with underlying cardiac risk factors and electrolyte disturbance.

If patients develop any symptoms indicating arrhythmia or shifts of fluid/electrolytes during or after treatment (e.g. oedema, shortness of breath, increasing fatigue, cardiac failure), plasma electrolytes should be measured, ECG monitored and any abnormality treated appropriately.

If patients experience severe bloating, abdominal distension, or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms subside.

In people with swallowing problems, who need the addition of a thickener to solutions to enhance an appropriate intake, interactions should be considered, see section 4.5.

Ischaemic colitis

Post-marketing cases of ischaemic colitis, including serious, have been reported in patients treated with macrogol for bowel preparation. Macrogol should be used with caution in patients with known risk factors for ischaemic colitis or in case of concomitant use of stimulant laxatives (such as bisacodyl or sodium picosulfate). Patients presenting with sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis should be evaluated promptly.

Cases of oesophageal rupture (Boerhaave syndrome) associated with excessive vomiting after intake (see section 4.8) of macrogol 3350 with electrolytes for bowel preparation has been reported post-marketing, mostly in elderly patients. Advise patients to stop administration and seek immediate medical assistance if they experience incoercible vomiting and subsequent chest, neck, and abdominal pain, dysphagia, hematemesis or dyspnoea.

Plenvu contains 458.5 mmol (10.5 g) sodium per course of treatment. This should be taken into consideration for patients on a controlled sodium diet. Only a proportion of the sodium is absorbed, see section 5.2.

Plenvu contains 29.4 mmol (1.1 g) potassium per course of treatment. This should be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.

4.5. Interaction with other medicinal products and other forms of interaction

The interaction of Plenvu with other medicinal products has not been studied. Theoretically, medicinal products taken orally (e.g. oral contraceptive pill) one hour before, during and one hour after Plenvu administration may be flushed from the gastrointestinal tract unabsorbed. The therapeutic effect of drugs with a narrow therapeutic index or short half-life may be particularly affected.

Plenvu may result in a potential interactive effect if used with starch-based food thickeners. Macrogol ingredient counteracts the thickening effect of starch, effectively liquefying preparations that need to remain thick for people with swallowing problems.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of Plenvu active ingredients in pregnant women. Animal studies have shown indirect harmful effects with respect to reproductive toxicity (see section 5.3). Clinically, no effects during pregnancy are anticipated, since systemic exposure to macrogol 3350 is negligible.

As a precautionary measure, it is preferable to avoid the use of Plenvu during pregnancy.

Breast-feeding

It is unknown whether Plenvu active ingredients/metabolites are excreted in human milk. There is insufficient information on the excretion of Plenvu active ingredients/metabolites in human milk.

A risk to the newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to abstain from Plenvu therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data on the effects of Plenvu on fertility in humans. There were no effects on fertility in studies in male and female rats (see section 5.3).

4.7. Effects on ability to drive and use machines

Plenvu has no influence on the ability to drive and use machines.

4.8. Undesirable effects

Diarrhoea is an expected outcome of bowel preparation. Due to the nature of the intervention, undesirable effects occur in the majority of patients during the process of bowel preparation. Whilst these vary between preparations, nausea, vomiting, bloating, abdominal pain, anal irritation and sleep disturbance commonly occur in patients undergoing bowel preparation. Dehydration may occur as a result of diarrhoea and/or vomiting.

Data from clinical studies are available in a population of over a thousand subjects treated with Plenvu in which undesirable effect data were actively elicited.

The table below is a list of treatment emergent adverse events reported in the clinical studies of Plenvu.

The frequency of adverse reactions to Plenvu is defined using the following convention:

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000)

Not known (cannot be estimated from the available data)

Very common

(≥1/10) #

Common

(≥1/100 to <1/10)

Uncommon

(≥1/1,000 to <1/100)

Frequency Not Known

Gastrointestinal disorders

Vomiting, Nausea

Abdominal distension, Anorectal discomfort, Abdominal pain, Abdominal pain upper, Abdominal pain lower

Oesophageal rupture (Boerhaave syndrome)

Immune system disorder

Drug hypersensitivity

Metabolism and nutrition disorders

Dehydration

Nervous system disorders

Headache, Migraine, Somnolence

Seizure

General disorders and administration site conditions

Thirst*, Fatigue, Asthenia, Chills**, Pains, Aches

Cardiac disorders

Palpitation, Sinus tachycardia

Vascular disorders

Transient increase in blood pressure, Hot flush

Investigations

Transient increase in liver enzymes***

Hypernatraemia, Hypercalcaemia, Hypophosphataemia, Hypokalaemia, Decreased bicarbonate, Anion gap increased/ decreased, Hyperosmolar state

*Thirst includes the Preferred Terms; Thirst, Dry mouth and Dry throat

**Chills includes the Preferred Terms; Chills, Feeling hot and Feeling cold

***Transient increase in liver enzymes includes the Preferred Terms; ALT increased, AST increased, GGT increased, Hepatic enzymes increased, Transaminases increased

# No adverse events with a frequency of “very common” were reported during the clinical trials.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

In case of gross accidental overdose, where diarrhoea is severe, fluid replacement and electrolyte correction may be necessary.

💬 Ask about this leaflet

Ask anything about Plenvu powder for oral solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Medicines containing Ascorbic acid, Macrogol 3350, Potassium chloride, Sodium ascorbate, Sodium chloride, Sodium sulfate, anhydrous

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →